Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Bisphosphonates adherence for treatment of osteoporosis.

Vieira HP, Leite IA, Araújo Sampaio TM, Dos Anjos de Paula J, do Nascimento Andrade A, de Abreu LC, Valenti VE, Goulart FC, Adami F.

Int Arch Med. 2013 May 24;6(1):24. doi: 10.1186/1755-7682-6-24.

2.
3.

Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.

Rossini M, Viapiana O, Gatti D, Adami S.

Clin Ther. 2009 Jul;31(7):1497-510. doi: 10.1016/j.clinthera.2009.07.018. Review.

PMID:
19695399
4.

A systematic review of osteoporosis medication adherence and osteoporosis-related fracture costs in men.

Mikyas Y, Agodoa I, Yurgin N.

Appl Health Econ Health Policy. 2014 Jun;12(3):267-77. doi: 10.1007/s40258-013-0078-1. Review.

PMID:
24477429
5.
6.

Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis.

Cotté FE, Fardellone P, Mercier F, Gaudin AF, Roux C.

Osteoporos Int. 2010 Jan;21(1):145-55. doi: 10.1007/s00198-009-0930-1.

7.

Adherence and occurrence of fractures after switching to once-monthly oral bisphophonates.

Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA.

Pharmacoepidemiol Drug Saf. 2010 Dec;19(12):1233-40. doi: 10.1002/pds.2048.

9.

Bisphosphonates for steroid-induced osteoporosis.

Allen CS, Yeung JH, Vandermeer B, Homik J.

Cochrane Database Syst Rev. 2016 Oct 5;10:CD001347. Review.

PMID:
27706804
10.

Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.

Health Quality Ontario..

Ont Health Technol Assess Ser. 2006;6(20):1-180.

11.

Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups.

Burch J, Rice S, Yang H, Neilson A, Stirk L, Francis R, Holloway P, Selby P, Craig D.

Health Technol Assess. 2014 Feb;18(11):1-180. doi: 10.3310/hta18110. Review.

12.

A review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland.

Lippuner K, Pollock RF, Smith-Palmer J, Meury T, Valentine WJ.

Appl Health Econ Health Policy. 2011 Nov 1;9(6):403-17. doi: 10.2165/11592210-000000000-00000. Review.

PMID:
21910511
13.

How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.

Gold DT, Alexander IM, Ettinger MP.

Ann Pharmacother. 2006 Jun;40(6):1143-50. Review.

PMID:
16735667
14.

The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.

McHorney CA, Schousboe JT, Cline RR, Weiss TW.

Curr Med Res Opin. 2007 Dec;23(12):3137-52. Erratum in: Curr Med Res Opin. 2008 Mar;24(3):707.

PMID:
17988435
15.
16.
17.

Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors.

Cadarette SM, Solomon DH, Katz JN, Patrick AR, Brookhart MA.

Osteoporos Int. 2011 Mar;22(3):943-54. doi: 10.1007/s00198-010-1309-z.

18.

Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.

Cole RE.

Postgrad Med. 2011 Mar;123(2):131-44. doi: 10.3810/pgm.2011.03.2271. Review.

PMID:
21474901
19.

Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.

Lai PS, Chua SS, Chew YY, Chan SP.

J Clin Pharm Ther. 2011 Oct;36(5):557-67. doi: 10.1111/j.1365-2710.2010.01210.x.

PMID:
21916908
20.

Balloon kyphoplasty: an evidence-based analysis.

Health Quality Ontario..

Ont Health Technol Assess Ser. 2004;4(12):1-45.

Supplemental Content

Support Center